AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$LQDA

SINGH RAMAN sold $1.2M of LQDA

SINGH RAMAN sold 17,492 shares of Liquidia Corp (LQDA) at an average of $67.43 ($66.16–$68.62, $1.18M total) across 2 trades over 2026-09-11 to 2026-09-14.

Original reporting
SEC EDGAR · SINGH RAMAN
Published Sep 15, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, a primary source filing.

02

Market read

First‑report insider sale; modest materiality for a micro‑cap, may influence short‑term price.

03

What to watch

Company's recent pipeline developments could offset concerns from the sale.

Relevance 6/10Novelty 7/10Timing: Filed Sep 15, 2026 (post‑market)

Background

Liquidia Corp (NASDAQ:LQDA) is a biotech firm developing drug delivery platforms.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Director Singh Raman sold 17,492 shares for $1.18M, reducing his stake to 44,637 shares.

Expected impact

Modest short-term dip, potential 1-2% decline.

Evidence & confidence

Sale size is material for a micro‑cap, but no 10b5‑1 plan and insider remains a significant holder.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No broader regional effect.

Global

Limited to investors tracking micro‑cap biotech stocks.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

  • Director
    Singh Raman

    Director of Liquidia Corp who sold shares.

  • Company
    Liquidia Corp

    Biotech company subject of the Form 4 filing.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min